Carriers of rare damaging CCR2 genetic variants are at lower risk of atherosclerotic disease.
Marios K GeorgakisRainer MalikNatalie R HasbaniGabrielle ShaktAlanna C MorrisonNoah L TsaoRenae JudyBraxton D MitchellHuichun XuMay E MontasserRon DoEimear E KennyRuth J F LoosJames G TerryJohn Jeffrey CarrJoshua C BisBruce M PsatyW T LongstrethKendra A YoungSharon M LutzMichael H ChoJai BroomeAlyna T KhanFei Fei WangNancy Heard-CostaSudha SeshadriRamachandran S VasanNicholette D PalmerBarry I FreedmanDonald W BowdenLisa R YanekBrian G KralLewis C BeckerPatricia A PeyserLawrence F BielakFarah AmmousApril P CarsonMichael E HallLaura M RaffieldStephen S RichWendy S PostRussel P TracyKent D TaylorXiuqing GuoMichael C MahaneyJoanne E CurranJohn E BlangeroShoa L ClarkeJeffrey W HaesslerYao HuThemistocles L AssimesCharles KooperbergScott M DamrauerJerome I RotterPaul S de VriesMartin DichgansPublished in: medRxiv : the preprint server for health sciences (2023)
variants have a lower burden of atherosclerosis and lower lifetime risk of myocardial infarction. In conjunction with previous evidence from experimental and epidemiological studies, our findings highlight the translational potential of CCR2-targeting as an atheroprotective approach.